[Study on colorectal cancer using air-liquid interface organoid culture method]

Area of Science:

• Oncology
• Translational Medicine
• Drug Development

Background:

• Colorectal cancer presents significant unmet medical needs, with increasing fatalities linked to anti-cancer drug resistance.
• Existing experimental models struggle to accurately replicate the complex tumor microenvironment, hindering the development of effective therapies.
• Personalized treatment strategies are crucial for overcoming drug resistance in individual colorectal cancer patients.

Purpose of the Study:

• To review the current challenges in colorectal cancer drug therapy, particularly focusing on drug resistance.
• To introduce a novel organoid culture method for developing targeted drugs.
• To establish a more accurate preclinical model for studying colorectal cancer drug resistance.

Main Methods:

• Utilizing a human colon tissue-derived air-liquid interface organoid culture method.
• Developing new targeted drug candidates for colorectal cancer treatment.
• Evaluating the efficacy of novel drugs in the established organoid model.

Main Results:

• The air-liquid interface organoid model successfully recapitulates key aspects of the in vivo tumor microenvironment.
• The developed targeted drugs show potential in overcoming anti-cancer drug resistance in the organoid model.
• This approach facilitates the study of patient-specific drug responses.

Conclusions:

• The human colon tissue-derived air-liquid interface organoid culture is a promising platform for developing novel colorectal cancer therapies.
• This method offers a viable strategy to address the challenge of anti-cancer drug resistance.
• Further development and application of this model can lead to more personalized and effective treatments for colorectal cancer patients.